Methamphetamine abuse is spreading rapidly throughout the United States and is characterized by significant health consequences. The powerfully rewarding effects of methamphetamine are attributed to multiple neuropharmacological actions such as its ability to block plasma membrane transporters of all monoamines, reduce dopamine transporter expression, and inhibit monoamine oxidase activity while increasing tyrosine hydroxylase activity. However, subsequent neuroreceptor changes including monoamine deficits complement this striking increase in monoamine release. Chronic methamphetamine abuse, as studied via selfadministration paradigms in rodents, causes progressive dopaminergic neurotoxicity, a neuroanatomical change accompanied by increasing drug tolerance and escalating intake, two behavioral parameters of addiction. We have recently proposed that methamphetamine covalently glycates endogenous proteins. Such an event spurs antibody production against these immunoconjugates, possibly leading to drug sequestration by antibody binding of drug. Here we demonstrate that this drug-dependent glycation mechanism is operative in vivo through the dose-dependent detection of antibodies against methamphetamine-derived advanced glycation end products in rats chronically self-administering methamphetamine. Furthermore, increased levels of proinflammatory cytokines, evidence of potent immunoactivation, were also detected. Given the known role of advanced glycation end products in the alteration of protein function in vivo and the participation of these molecules in various diseases, methamphetamine-derived advanced glycation end products provide an unrecognized molecular mechanism for the development of vasculitis and other cardiovascular maladies reported with high incidence in chronic methamphetamine users.
A s alarming as the propensity of methamphetamine to induce severe addiction and health-related consequences is the rapid spread of methamphetamine abuse across the United States. Whereas before 2001 methamphetamine use occurred predominantly in the western United States, it now is extending rapidly throughout the United States and across different ethnic groups (1) . The threat that methamphetamine now poses to society underscores the need to more thoroughly examine the ramifications of chronic methamphetamine abuse.
A potent psychostimulant, methamphetamine functions as a substrate for both dopamine and serotonin transporters, entering presynaptic terminals to displace vesicular neurotransmitters (2) . Its powerful rewarding properties stem from the subsequent activation of the mesolimbic and nigrostriatal dopamine pathways, changes in which lead to the neuroadaptations in the learning and reward systems characteristic of addictive states (2, 3) . Striatal dopaminergic neuron toxicity accompanies the increasing compulsion for drug-taking, but a molecular mechanism for such neurotoxicity has not been fully elucidated. Instead, research into the neurotoxic effects of methamphetamine has been reserved for paradigms involving acute, high doses of drug; chronic methamphetamine dosing schedules are implemented primarily in studies of addictive behavior or longterm neuro-and immunomodulation (4) (5) (6) (7) (8) (9) . It has been shown that single and repeated high doses of drug result in hyperthermia, lowered threshold for seizure genesis, and prolonged bouts of status epilepticus (10) . This behavioral display of methamphetamine toxicity is accompanied by well documented signs of neurotoxicity, including blood-brain barrier (BBB) disruption in limbic regions and dopaminergic neuronal death (10, 11) . Given that such severe manifestations develop over a relatively short time frame, peripheral signs of methamphetamine toxicity, which often require more chronic methamphetamine abuse, are largely ignored. However, sustained methamphetamine abuse and addiction produce serious cardiovascular consequences, including arrhythmias, intracranial hemorrhage, congestive heart failure, and vascular complications (2, 8, 12) .
Our recent investigations into the chemical reactivity of nicotine metabolites (13) (14) (15) led us to consider endogenous biochemical reactions in which methamphetamine may participate before reaching the brain and mediating its well characterized stimulant effects. In this context, protein glycation is the process by which reducing sugars react reversibly with nucleophilic free amino groups of proteins to produce N-substituted glycosylamines (16) . Subsequent intramolecular Amadori rearrangement converts Schiff bases into more stable aminoketoses, which may undergo further oxidation to form reductones, shortchain hydrolytic fission products, and nitrogenous polymers (17) . Glycation reactions, collectively termed the Maillard reaction, have been studied for decades in the food industry in the development of flavor and color; however, Maillard products can also assume a biologically hazardous role when synthesized in vivo. Acquiring the ability to cross-link proteins, these irreversible reaction products, termed advanced glycation end products (AGEs), have gained notoriety for their participation in a range of disease pathologies, including diabetes mellitus and Alzheimer's dementia (18) (19) (20) . More generally, long-lived AGEs can modify protein function (21) , initiate a wide range of deleterious cellular responses, and, in the context of the circulatory system, form deposits along arterial walls, causing inadvertent immune effector function recruitment and subsequent vascular damage (17, 22) . This article is a PNAS Direct Submission.
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Results and Discussion
Anti-Methamphetamine AGE Antibody Detection. We previously demonstrated the ability of methamphetamine to glycate proteins, which leads to a subsequent immune response against the drug (Fig. 2 A) (23) . However, this study entailed immunizing mice with synthetically prepared methamphetamine AGE; although it validated our hypothesis, it did not directly implicate this process in vivo. To examine the potential of in vivo methamphetamine glycation, catheterized rats were divided into groups, long access (LgA) and short access (ShA), based on the duration of time each day (6 and 1 h, respectively) an animal was given access to methamphetamine. The rats were trained in a drug self-administration paradigm ( Fig. 1) and then allowed to escalate methamphetamine intake over a prolonged period (Ն87 days) (24) . The extent of methamphetamine AGE-induced antibody production was compared between the different rat groups and, indeed, a direct relationship was observed between the level of methamphetamine intake and the respective antibody titers against methamphetamine-glycated proteins (Fig.  2B) . Statistical ANOVA confirmed the significantly increasing antibody titers in ShA and LgA sera to methamphetaminemodified glycated mouse serum albumin (MSA). Furthermore, comparison of ELISA signals (repeated measure) between LgA and drug-naive (DN) serum antibodies (Group) for methamphetamine AGE rat serum albumin (RSA) and methamphetamine AGE MSA (Antigen) by three-way ANOVA of repeated measures (Group, Antigen, and ELISA titration) demonstrated the main effect of Group [Group ϫ ELISA titration signal, F (7, 224) ϭ 31.773, P Ͻ 0.001]. Antibodies generated in LgA rats were capable of binding methamphetamine AGE derived from self-proteins (RSA) as well as from foreign proteins (MSA) to a significantly greater extent than DN serum antibodies as measured by Student's t test (with the null hypothesis H 0 that the LgA group is equal to the DN group, P Ͻ 0.0001 for either methamphetamine AGE RSA or methamphetamine AGE MSA).
The more robust methamphetamine dose escalation of LgA rats compared with ShA rats suggests the development of drug tolerance, a trend that mirrors the increasing antibody titers. LgA rats administered an average of 7 mg/kg methamphetamine daily during the 6-h self-administration session, which is proportional to the level of methamphetamine intake displayed by chronic drug users (25) . A 6-h self-administration session daily translates to continual immune challenge by methamphetamine in comparison to the 1-h daily exposure (ShA), particularly when the half-life of methamphetamine in rats is considered (t1 ͞2 Ϸ 1 h) (26) . The detection of antibody titers in ShA rats, albeit at reduced levels compared with LgA rat sera, suggests that, even at a relatively low dose, appreciable methamphetamine glycation occurs with concomitant anti-methamphetamine AGE antibody production in the absence of an added adjuvant or other immunostimulatory molecules. It follows that longer daily exposure to drug would then serve as the equivalent of multiple booster injections in its ability to encourage antibody production. Interestingly, prior research on active methamphetamine vaccine development required that a methamphetamine-keyhole limpet hemocyanin (KLH) immunoconjugate be coinjected with an adjuvant to produce even minimal titers (27) . Based on our data, not only are the endogenous methamphetamine AGE proteins sufficiently immunogenic to spur antibody production, but, given that methamphetamine possesses immunosuppressive properties similar to other drugs of abuse (28), the resulting activation also overcomes this initial immunosuppression despite a lack of adjuvant priming.
Immunomodulation by Methamphetamine AGEs. Upon detecting a foreign threat, the immune system calls on various signaling molecules to convert the message of immunoactivation to the generation of a response that includes inflammation and antibody production. We speculated that, as a consequence of methamphetamine glycation, peripheral cytokine expression levels would be altered in response to methamphetamine AGE production, given both the reports of immunomodulation by methamphetamine and the knowledge that AGEs cause damage upon their deposition along vascular walls (18, 29) . However, few studies on methamphetamine-induced immunomodulation have After the initial baseline sessions in which all rats acquired stable self-administration of methamphetamine, rats were divided into two groups, ShA and LgA, according to drug availability for the duration of the study. Both ShA and LgA rats displayed escalation of drug intake, with the rapidity of escalation being drug-dose-dependent (6, 41). focused on cytokine detection in the periphery as opposed to the CNS. Our rationale was that in the presence of methamphetamine AGEs, as well as anti-methamphetamine AGE antibodies, either of these molecules could significantly modulate cytokine expression. To test this hypothesis, the expression levels of TNF-␣ and IL-1␤, two major proinflammatory cytokines that mediate macrophage activation and vasculature permeance, were first considered (Fig. 3) . A substantial (fivefold) elevation of TNF-␣ in LgA sera over DN sera (P Ͻ 0.05) was observed. Because TNF-␣ and other T helper 2 (T H 2) cytokines stimulate B cells to promote antibody production, the upward trend of TNF-␣ is in agreement with the generation of antibodies against methamphetamine AGE proteins. IL-1␤ levels were reduced in groups exposed to chronic low doses (ShA rats) but were increased over normal levels in groups exposed to chronic high doses (LgA rats) of methamphetamine intake (with the null hypothesis H 0 that the LgA group is equal to the ShA group, P Ͻ 0.025). This biphasic behavior suggests that methamphetamine first induced suppression of IL-1␤ production in ShA rats; however, the more continual methamphetamine-mediated immune challenge experienced by LgA rats was accompanied by IL-1␤ activation.
A number of other cytokine molecules directly linked to AGE exposure were up-regulated in a dose-dependent manner in methamphetamine self-administering rats. Among these cytokines, VEGF was elevated sixfold in LgA rats over the normal levels observed in DN rats (P Ͻ 0.01) and doubled in ShA rats (P ϭ 0.013) (Fig. 3) . AGEs have been shown to increase VEGF production, with this up-regulation dependent on the duration of AGE stimulation (30) . AGE-mediated VEGF up-regulation, which has been implicated in the development of diabetic retinopathy and nephropathy, has not been investigated in conjunction with the progression of chronic methamphetamine addiction. This connection is feasible because AGE-modified proteins produce myocardial stiffness, plaque formation, and vascular damage, the latter seen in the pathology of chronic methamphetamine addicts.
Importantly, these data imply that limited daily access to drug, as tested in ShA rats, was sufficient to potentiate overexpression of VEGF, a trait not seen in the other cytokines evaluated. We hypothesize that even recreational methamphetamine use at lower doses may sufficiently increase VEGF to potentially detrimental levels (31) . As a corollary, such cardiovascular damage has been documented in both non-human and human methamphetamine abusers (32) (33) (34) . Indeed, rats have been reported to suffer substantial tissue damage including hemorrhage and interstitial vessel dilatation upon chronic methamphetamine self-administration (35) .
In addition to VEGF-induced vascular dysfunction in disease states, long-term VEGF exposure hyperpermeabilizes the BBB (36) . As a potential consequence, many of the cytokines examined may have been produced in association with microgliosis in the CNS, only to diffuse across the leaky BBB for detection peripherally. Conversely, the central effects attributed to chronic methamphetamine abuse may stem from influx of drug and peripheral molecules through a compromised BBB; discrimination between these two mechanisms will require further study. However, because comparable AGE production and increased VEGF levels mediate the more severe vascular complications of diabetes mellitus, this mechanism lends itself well as a plausible hypothesis for the vascular complications associated with methamphetamine use.
IFN-␥, a cytokine produced and secreted by activated T lymphocytes, was previously shown to be reduced in mice exposed to methamphetamine (8) . Although we observed IFN-␥ to be down-regulated given shorter daily methamphetamine exposure (with the null hypothesis H 0 that the ShA group is equal to the DN group, P ϭ 0.01), this reduced level was not maintained in rats with higher daily methamphetamine intake (LgA rats) (Fig. 3) . Our observed trend of decreased IFN-␥ and increased TNF-␣ was in agreement with previous studies (8) .
In conjunction with the above cytokines, several chemokines were altered in the periphery of drug self-administering rats. In particular, chemokines with direct relevance to the immune response, such as monocyte chemoattractant protein (MCP1 or CCL2), were increased upon sustained exposure to methamphetamine (with the null hypothesis H 0 that the LgA group is equal to the DN group, P Ͻ 0.05) (37) . Other chemokines, such as fractalkine and cytokine-induced neutrophil chemoattractant 2 (CINC2), displayed similar biphasic behavior with regard to drug dose, comparable with our cytokine analysis.
We were gratified to observe a correlation of drug intake within both antibody titers and in modulation of cytokine levels. Our results concerning immunomodulation by methamphetamine are in direct accordance with previous studies (8, 28) . However, a critical difference exists in the methamphetamine dose used in previous reports to elicit such noticeable consequences and the dose we have proven sufficient to mediate similar alterations in immune function. Whereas previously rats were injected with drug for 12 weeks with an experimenterregulated dose escalation from 15-40 mg/kg, our selfadministration dose escalation paradigm produces maximum methamphetamine intake of Ϸ7 mg/kg distributed over a 6-h session of methamphetamine availability (LgA rats). Given the notably short half-life of methamphetamine in rats of 15-70 min (38) , coupled with limited access in the form of daily injections or 1-h self-administration sessions, rats were not permitted to assuage plummeting dopamine levels during withdrawal via increased drug administration. It is believed that the withdrawal state, which encourages further drug intake so as to maintain elevated blood concentrations of drug, precipitates tolerance to the rewarding effects of methamphetamine. Implementation of a longer self-administration session (LgA) allowed recognition of distinct differences between ShA and LgA intake patterns. LgA rats self-administered substantially more drug during the first of 6 h as compared with the first (and only) hour of ShA rats. In terms of addictive behavior, LgA rats displayed gradual dose escalation over the course of the study, with the end result being that LgA rats administered substantially more drug per day as compared with the low and stable intake of ShA rats. It has been hypothesized that such escalation of drug intake may represent a major component in the development of addiction (39-42). 3 . Modulation of relevant cytokine and chemokine levels in response to methamphetamine intake. Sera samples analyzed were obtained from ShA (gray bars) and LgA (black bars) rats self-administering methamphetamine for 1 h daily and 6 h daily, respectively, for a period of 87 days. Data are expressed as mean fold-increase over DN levels Ϯ SEM. * , P Ͻ 0.05; ** , P Ͻ 0.01; significance in change compared with DN levels. †, P Ͻ 0.05; with the null hypothesis H 0 that the LgA group is equal to the ShA group.
Because the mechanism of action for the rewarding effects of methamphetamine within the brain clearly justifies its addictive properties, researchers have neglected the influence of the pattern of drug-taking on the etiology of methamphetamine abuse. Methamphetamine displaces vesicular and intracellular dopamine and serotonin, and inhibits both plasmalemmal monoamine and intraneuronal vesicular transporters. These actions directly stimulate the mesolimbic reward pathways, and are counterbalanced by dopaminergic signaling deficits and other neuroadaptive changes such as in brain stress systems that contribute to aversive withdrawal states. This serves as a direct impetus to ''binge and run'' patterns of drug intake and dose escalation with developing tolerance, behavioral traits of methamphetamine abuse that were unobserved in previous paradigms but that emerged in the 6-h self-administration sessions. We hypothesize that these components of methamphetamine abuse dynamically affect the magnitude of the observed immunological consequences, especially given that the average total daily intake of drug even in LgA rats was noticeably less compared with the methamphetamine doses used previously to elicit immunological, neurobiological, or pharmacological responses. Regardless, results from ShA rats attest to the potential consequences of limited methamphetamine exposure, which may approximate more recreational methamphetamine abuse among human users. The ShA data illustrate that an acute methamphetamine binge is not necessary to evoke severe health consequences but rather that even chronic, low-level drug intake is sufficient to affect immune function.
These results conclusively demonstrate that the in vivo formation of methamphetamine-glycated proteins is sufficient to elicit an aberrant immune response. In addition to the neurotoxicity and disruption of the BBB that occur after an acute high dose of methamphetamine (8), our results argue that the methamphetamine AGE-induced elevation of VEGF, given chronic methamphetamine intake, provides an additional long-term mechanism for BBB permeance. Previously, the stereotyped reaction to high-dose injections of methamphetamine, namely seizures and hyperthermia, was assumed to cause BBB damage because these manifestations of drug overdose have the potential to cause neurotoxicity. However, as reported in the literature, BBB disruption is separate from seizure genesis and hyperthermia (8) . The failure of methamphetamine to spur seizures in our self-administering rats does not preclude these substantially lower chronic doses from causing a similar increase in BBB permeance via a distinct mechanism. Our data highlight the utility of chronic dose escalation paradigms by uncovering the possibility that a molecular mechanism more complex than the severe phenotypes displayed during methamphetamine overdose may induce the altered pathology of methamphetamine addicts.
Furthermore, other cardiovascular problems observed in methamphetamine addicts require chronic, not acute, methamphetamine use for their development (43, 44) . In such cases, the methamphetamine dose-dependence obser ved in antimethamphetamine AGE antibody production and corresponding cytokine modulation parallels these clinical reports of vascular inflammation and deterioration. Because methamphetamine provokes a robust microglial response that correlates with both methamphetamine dose and the appearance of methamphetamine-related neurotoxicity, researchers have remained captivated by methamphetamine-induced inf lammatory responses in the CNS and have largely ignored the repercussions of methamphetamine use in the periphery. Our findings form the basis for a previously uncharacterized molecular mechanism justifying the deleterious clinical observations in methamphetamine addicts and validate the need for further exploration into methamphetamine-induced damage in the peripheral nervous system and vasculature.
Materials and Methods
Methamphetamine Self-Administration. Blood samples were collected from two groups of rats used in two separate studies (6, 41) . Detailed methods of surgery and apparatus are described elsewhere (6) .
Briefly, male Wistar rats (Charles River Laboratories, Wilmington, MA), weighing 250-300 g at the start of the experiment, were housed three per cage in a temperature-controlled vivarium under a reversed 12:12-h light/dark cycle (lights off at 0800 hours). Food and water were available ad libitum throughout the study. All experiments were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute and conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
Rats with an indwelling catheter were trained to selfadminister methamphetamine (0.05 mg/kg per infusion) in 1-h sessions (baseline sessions) under a fixed-ratio 1 (FR 1) schedule. After six baseline sessions, the rats were divided into two groups balanced by the number of injections per session during the last three baseline sessions. During the escalation period, one group, ShA rats, was allowed to self-administer 0.05 mg/kg per infusion of methamphetamine for 1 h per day under an FR 1 schedule, whereas the other group, LgA rats, was allowed to do so for 6 h per day. Escalation sessions lasted for a minimum of 87 days.
Upon completion of the dose-escalation period, blood was collected from DN rats (n ϭ 4), ShA rats (n ϭ 10), and LgA rats (n ϭ 13) by cardiac puncture, to which EDTA (final concentration of 5 M) was added. Sera were obtained by centrifugation, and serum samples were stored at 4°C for immediate use or Ϫ80°C for future use.
For self-administration, (S)-(ϩ)-methamphetamine hydrochloride was provided by the National Institute on Drug Abuse (Rockville, MD). Methamphetamine was dissolved in sterile 0.9% saline for self-administration. Methamphetamine solutions were prepared for each rat based on its body weight and were updated every 2-3 days.
Apparatus. Behavioral training was conducted in operant conditioning chambers (45) . Briefly, during experimental sessions, each rat was placed in an operant chamber, which was placed in a light-and sound-attenuating cubicle (28 ϫ 26 ϫ 20 cm; Med Associates, St. Albans, VT). The front door and the back wall of the chamber were made of transparent plastic, and the sidewalls were made of stainless steel. The chamber had two retractable response levers mounted on a sidewall and a food hopper located between the levers. A stimulus light was mounted above each lever. A drug injection was delivered by a syringe pump (Razel Scientific Research Instruments, Fairfax, VT) located on top of the cubicle. Sessions were controlled and recorded by a personal computer with custom interface and software in the experimental room.
Experimental sessions were conducted daily during the dark (active) cycle. Immediately before a session, rats were transferred from the vivarium to an experimental room where operant chambers were located. After being flushed with 0.9% saline, a rat's indwelling catheter was connected to a tube that exited the chamber through a metal spring and a swivel and was connected to a syringe pump. The start of a session was signaled by the presentation of two response levers into the chamber. Pressing the right lever resulted in the delivery of 0.1 ml of a drug injection over 4 s. During an injection, stimulus lights above both levers were illuminated and lasted throughout the time-out period (20 s) that followed each injection. Pressing the left lever was counted but had no other programmed consequences. The session was ended by the withdrawal of the levers from the chamber. After each session, the catheter was filled with 0.9% saline containing heparin (30 units per ml) and the rat was returned to the home cage.
Methamphetamine Protein Glycation. Glucose (200 mM) was added to PBS (200 mM at pH 7.4) to obtain a glucose-enriched buffer. MSA or RSA was then dissolved in this buffer in a microcentrifuge tube to attain a final protein concentration of 10 mg/ml (final reaction volume of 1 ml). Immediately after the addition of protein, (S)-(ϩ)-methamphetamine was added to the reaction (0.77 M), and the solution was filtered through a 0.2-m syringe filter. The reactions were incubated at 37°C in the dark, and aliquots were removed after 15 days, diluted 1:1,000 with PBS, and analyzed by ELISA using rat serum for primary antibody incubation and commercially available horseradish peroxidase-conjugated goat anti-rat IgG heavy and light chains (H ϩ L) for secondary antibody incubation and detection. The plate was developed with the colorimetric reagent 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) and quenched with an equal volume of 2 M H 2 SO 4 , and the absorbance was measured on an ELISA plate reader at 450 nm.
Competition ELISA. A 96-well Costar ELISA plate (Corning Life Sciences, Corning, NY) was coated with 125 ng of protein (MSA, RSA, methamphetamine AGE MSA, or methamphetamine AGE RSA) for 1 h at 37°C and then blocked overnight at 4°C with 50 l of Blotto [5% (wt/vol) nonfat milk powder in PBS]. Typically, 25 l of an initial 1:10 dilution of rat serum in Blotto was added to the first row and then serially diluted down the plate, followed by incubation for 1.5 h at 37°C. After washing, 25 l of a 1:2,000 dilution of a goat anti-rat/horseradish peroxidase conjugate in Blotto was added and incubated for 1 h at 37°C. The plate was developed with the colorimetric reagent TMB and quenched with an equal volume of 2 M H 2 SO 4 , and the absorbance was measured on an ELISA plate reader at 450 nm.
Cytokine/Chemokine Analysis. Rat serum was assessed for the presence of multiple cytokines. Antibody array membranes (rat cytokine antibody array I; RayBiotech, Norcross, GA) were first blocked for 30 min with the provided blocking buffer, to which rat sera were subsequently added for a final 10-fold dilution of the sera. Membranes were then incubated for 2 h at room temperature with shaking, and the cytokines were detected according to the manufacturer's instructions.
Data Analysis. All data were reported as mean Ϯ SEM. To verify that LgA rats were self-administering higher methamphetamine doses than ShA rats and that the LgA rats displayed a different pattern of dose escalation over the course of the 87-day or longer self-administration study, the following statistical analysis was completed. Data (number of infusions or mg/kg) obtained during the escalation phase were subjected to a two-way ANOVA with Group (ShA of 1 h vs. LgA of 6 h) as one factor and Time (days) as a within-subjects factor. A second ANOVA was used for the 1-h data with Group (ShA vs. LgA) as one factor and Time (day 5) as a within-subjects factor. All post hoc comparisons were performed by using the Student-NewmanKeuls test. All antibody and cytokine levels were first compared by three-way repeated-measures ANOVA with Group (DN, LgA, or ShA), Antigen (MSA, RSA, methamphetamine AGE MSA, or methamphetamine AGE RSA coating the ELISA plate), and Signal (from the ELISA titrations) as factors or by one-way ANOVA for Group, respectively. Once significance was determined, further comparative statistics were conducted by using unpaired Student's t test among groups to analyze the effect of differing durations of methamphetamine exposure on the resulting immune response. P Ͼ 0.05 was used as a criterion for statistical significance.
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